Benzinga · Oct 22, 2026
Gyre Therapeutics Signs Employment Agreement For Ying To Continue As CEO, Thomas Eastling As CFO
https://www.sec.gov/ix?doc=/Archives/edgar/data/1124105/000114036126040506/ef20080299_8k.htm
GY
NASDAQ · GYRE
Gyre Therapeutics, Inc.
Healthcare · Biotechnology
$4.56
Down-$1.86 (-28.94%)
Updated Oct 31, 2026, 9:11 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 715.86M
- P/E ratio
- 56.8
- Dividend yield
- 0.00%
- 52-week range
- $5.44 – $8.51
- Volume
- 394.08K
- Avg. volume
- 76.81K
Price performance · GYRE
GYRE price history
1M range · 0 trading sessions · Daily adjusted prices
GYRE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest GYRE news
The latest Smart Investors Daily articles mentioning GYRE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GYRE research
Overview
Company profile and research snapshot.
Company profile
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $17.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 10, 2025 | Jefferies | Buy | — |
| Aug 26, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that Company management will participate in the Cantor Global Healthcare Conference and the Morgan Stanley Healthcare Conference, both being held this month in New York, NY. Information about both conferences is below: Cantor Global Healthcare Confere
Yahoo · Aug 7, 2026
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Aug 7, 2026
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026 SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced financial results for the secon
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
